Houston based life science startup, ThromboVision announced today the closing of a $4 million Series A round of financing from National Health Care Services and a group of private investors. The company plans on using the funds to build an infrastructure and fund clinical trials of their ThromboGuide product towards FDA approval. The system will help physicians individualize antiplatelet therapy that they use to prevent heart attacks, strokes and stent occlusions.
In conjunction with the closing of this round, the company also announced securing a $750,000 credit facility with Silicon Valley Bank.
0 Responses to “ThromboVision Closes $4 Million Series A Financing”
Leave a Reply